Thomas Egenod

562 total citations
29 papers, 266 citations indexed

About

Thomas Egenod is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Thomas Egenod has authored 29 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Surgery. Recurrent topics in Thomas Egenod's work include Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (7 papers). Thomas Egenod is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (7 papers). Thomas Egenod collaborates with scholars based in France, United States and United Kingdom. Thomas Egenod's co-authors include Franck Morin, Olivier Molinier, Alexandra Langlais, Julien Mazières, Gérard Zalcman, Virginie Westeel, L. Brouchet, A. Lavolé, Marie-Ange Massiani and Marie Wislez and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Thomas Egenod

24 papers receiving 264 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Egenod France 8 211 179 23 20 20 29 266
Cristina Morelli Italy 8 125 0.6× 53 0.3× 12 0.5× 10 0.5× 16 0.8× 23 201
Hanako Kuhara Japan 10 117 0.6× 170 0.9× 18 0.8× 58 2.9× 21 1.1× 24 271
Marco Banini Italy 6 104 0.5× 93 0.5× 13 0.6× 9 0.5× 10 0.5× 15 164
Xiao-Zhong Chen China 7 58 0.3× 87 0.5× 27 1.2× 9 0.5× 8 0.4× 9 187
Goretti Hernández Spain 6 184 0.9× 133 0.7× 14 0.6× 10 0.5× 3 0.1× 18 228
Felice Granato United Kingdom 9 66 0.3× 187 1.0× 26 1.1× 29 1.4× 5 0.3× 29 249
Els Monsaert Belgium 6 174 0.8× 61 0.3× 9 0.4× 44 2.2× 5 0.3× 17 228
Daniel José Szor Brazil 8 86 0.4× 126 0.7× 15 0.7× 6 0.3× 11 0.6× 26 217
Leonor Vasconcelos de Matos Portugal 6 81 0.4× 28 0.2× 13 0.6× 8 0.4× 3 0.1× 21 125

Countries citing papers authored by Thomas Egenod

Since Specialization
Citations

This map shows the geographic impact of Thomas Egenod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Egenod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Egenod more than expected).

Fields of papers citing papers by Thomas Egenod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Egenod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Egenod. The network helps show where Thomas Egenod may publish in the future.

Co-authorship network of co-authors of Thomas Egenod

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Egenod. A scholar is included among the top collaborators of Thomas Egenod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Egenod. Thomas Egenod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roy, Pascalin, Sophie Laroumagne, C. Fournier, et al.. (2025). Role of Therapeutic Bronchoscopy in Malignant Central Airway Obstruction Due to Small Cell Lung Cancer: Results From the EpiGETIF Registry. Archivos de Bronconeumología. 61(7). 440–442.
2.
Stewart, G., et al.. (2025). 88P: Real-world occurrence of early-onset pulmonary events with brigatinib for advanced ALK+ NSCLC. Journal of Thoracic Oncology. 20(3). S64–S65.
3.
Mascaux, Céline, Laurent Greillier, L. Moreau, et al.. (2025). OA05.02 First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial. Journal of Thoracic Oncology. 20(10). S19–S19.
4.
Egenod, Thomas, et al.. (2024). The Use of Bronchial Rheoplasty in Emphysema Patients Previously Treated with Endoscopic Lung Volume Reduction: A Case Series. International Journal of COPD. Volume 19. 1791–1797. 1 indexed citations
5.
Cascone, Tina, Laura Bonanno, M. A. Lieberman, et al.. (2024). PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC. Journal of Thoracic Oncology. 19(10). S1–S2. 6 indexed citations
6.
7.
Damotte, Diane, Barbara Burroni, Audrey Mansuet‐Lupo, et al.. (2024). Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 8022–8022. 1 indexed citations
8.
Egenod, Thomas, Gaëtan Deslée, & Bruno Degano. (2023). Traitements endoscopiques de la BPCO. Revue des Maladies Respiratoires. 40(9-10). 820–833. 1 indexed citations
9.
Dupuis, Marion, et al.. (2023). Bronchoscopic lung volume reduction with endobronchial valves improves respiratory muscle function in patients with severe emphysema. Respiratory Medicine and Research. 84. 101030–101030. 1 indexed citations
10.
11.
Guibert, Nicolas, et al.. (2022). Bilateral endobronchial valves treatment for severe emphysema. ERJ Open Research. 8(2). 672–2021. 1 indexed citations
12.
Egenod, Thomas, Jérémy Tricard, S. Collot, et al.. (2021). Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk. International Journal of COPD. Volume 16. 1957–1965. 6 indexed citations
13.
14.
Girard, Nicolas, M. Duruisseaux, Virginie Avrillon, et al.. (2020). 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S865–S865. 1 indexed citations
15.
Egenod, Thomas, et al.. (2020). Endobronchials Valves: Impact of the 2 Step Approach on Pneumothorax Rates. A6867–A6867. 1 indexed citations
16.
Wislez, Marie, Julien Mazières, A. Lavolé, et al.. (2020). 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO). Annals of Oncology. 31. S794–S794. 40 indexed citations
17.
18.
Antoun, S., Hugues Morel, Pierre‐Jean Souquet, et al.. (2019). Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment. Journal of Cachexia Sarcopenia and Muscle. 10(4). 782–793. 20 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Morelli Breakdown of academic impact, for papers by Hanako Kuhara Breakdown of academic impact, for papers by Marco Banini Breakdown of academic impact, for papers by Xiao-Zhong Chen Breakdown of academic impact, for papers by Goretti Hernández Breakdown of academic impact, for papers by Felice Granato Breakdown of academic impact, for papers by Els Monsaert Breakdown of academic impact, for papers by Daniel José Szor Breakdown of academic impact, for papers by Leonor Vasconcelos de Matos
Rankless by CCL
2026